Autopsy report · NCT03708003

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

“The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 years 9 months before it stopped.
• 30 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Swiss Cancer Institute

Sponsor type

University, hospital or other

Conditions

Relapsed/Refractory Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Leukemia

Interventions

Ibrutinib; Venetoclax

Participants

30

Sites

11

Countries

Switzerland

Trials that died the same way

• Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
  “The trial met its primary endpoint.” (69% match in meaning)
• The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
  “The trial was terminated early due to futility in reaching the primary endpoint.” (68% match in meaning)
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
  “An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility” (64% match in meaning)
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
  “The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.” (63% match in meaning)
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
  “It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.